◼ Archived
Business
uniQure stock crashes as Huntington’s gene therapy data weaken
uniQure stock plummets alongside partner shares following disappointing clinical data from a Huntington's gene therapy trial.
2 trends tracked about this subject — the full history, oldest to newest below.
uniQure stock plummets alongside partner shares following disappointing clinical data from a Huntington's gene therapy trial.
UniQure shares tumble significantly as clinical trial data for its Huntington’s gene therapy draws conflicting reports.